Bone Loss Accompanying Medical Therapies

Dawson-Hughes, Bess
September 2001
New England Journal of Medicine;9/27/2001, Vol. 345 Issue 13, p989
Academic Journal
Editorial. Discusses two studies which report that the treatment of a primary medical condition can result in accelerated bone loss. Description of the two studies, which focused on bone loss during prostate cancer treatment with leuprolide and the effect of glucocorticoids on the bone mass of premenopausal women; Mention of possible factors that contribute to bone loss.


Related Articles

  • Preventing steroid-induced osteoporosis.  // American Family Physician;3/1/1995, Vol. 51 Issue 4, p965 

    Highlights the study published in the October 1994 issue of the journal `Australian Family Physician.' Osteoporosis during corticosteroid therapy; Adding calcium or/and calcitriol to corticosteroid.

  • Teriparatide tops alendronic acid for osteoporosis.  // Reactions Weekly;1/30/2010, Issue 1286, p5 

    The article discusses research on the effects of teriparatide compared with alendronic acid in treating glucocorticoid-induced osteoporosis, that references a study by K. G. Saag and colleagues published in the November 1, 2009 issue of "Arthritis and Rheumatism."

  • Osteoporosis risks with oral steroids.  // Pulse;6/10/2002, Vol. 62 Issue 23, p12 

    Examines the risk of osteoporosis associated with oral corticosteroids in patients with chronic obstructive pulmonary disease (COPD). Incidence of fracture among COPD patients; Anatomical manifestations of osteoporosis.

  • CORTICOSTEROID INDUCED OSTEOPOROSIS IN SEVERE MENSTRUAL ASTHMA. Chung, K.F.; Studd, J.W.; Barues, P.J.; Demson, D.M.; Mitchell, D.N.; Geddes, D.M. // BMJ: British Medical Journal (International Edition);8/15/92, Vol. 305 Issue 6850, p413 

    Focuses on the risk of developing osteoporosis with extended use of corticosteroids in treating severe menstrual asthma. Information on methotrexate; Symptoms of premenstrual asthma; Multifactorial actions by corticosteroids on the skeletal system.

  • Denosumab In Cancer Treatment-Induced Bone Loss.  // BioDrugs;2010, Vol. 24 Issue 6, p379 

    No abstract available.

  • RS3PE WITH PROSTATE ADENOCARCINOMA. ŞİLTE, Ayşe Duygu; ÖZKAN, Feyza Ünlü; AKTAŞ, İlknur // Turkish Journal of Geriatrics / Türk Geriatri Dergisi;2014, Vol. 17 Issue 3, p305 

    Relapsing seronegative symmetrical synovitis with pitting edema (RS3PE) is a clinical syndrome characterized by acute onset of symmetrical joint involvement with pitting edema of the hands and feet. The etiology and pathogenesis of RS3PE is still unknown, though environmental and infectious...

  • Using Restronate to Prevent Steroid-Induced Bone Loss. Miller, Karl E. // American Family Physician;2/15/2000, Vol. 61 Issue 4, p1167 

    Discusses the study `Risedronate Therapy Prevents Corticosteroid-Induced Bone Loss: A Twelve-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study,' by S. Cohen and colleagues published in the November 1999 issue of the `Arthritis Rheumatism' journal.

  • Avascular necrosis of the femoral heads after single corticosteroid injection. Gunal, Izge; Karatosun, Vasfi // CMAJ: Canadian Medical Association Journal;7/4/2006, Vol. 175 Issue 1, p32 

    Discusses a case of avascular necrosis of the femoral heads in a patient with minimal tenderness over his hips and mild limitation of his range of motion. Role of corticosteroid injection in the development of avascular necrosis; Other causes of avascular necrosis; Incidence rate of the medical...

  • Assessment of Etidronic Acid plus Alfacalcidol for the Treatment of Osteopenia in Steroid-Dependent Asthmatics: A Pilot Study of Five Cases. Tsugeno, H.; Nakai, M.; Okamoto, M.; Yokoi, T.; Takata, S.; Nishida, N.; Ashida, K.; Mitsunobu, F.; Yuki, H.; Tanizaki, Y.; Shiratori, Y. // Clinical Drug Investigation;2003, Vol. 23 Issue 2, p99 

    Objective: Osteoporosis is generally known to be one of the most serious adverse effects of long-term corticosteroid administration. Recently it was discovered that corticosteroid-induced osteoporosis occurs not only in trabecular bone but also in cortical bone, leading to a reduction in...


Read the Article

Other Topics